The Lancet Diabetes & Endocrinology

1. Lancet Diabetes Endocrinol26 Feb 2025

   Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials

   Meta-analysisT2D & other

2. Lancet Diabetes Endocrinol21 Feb 2025

   Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data

   Meta-analysis

3. Lancet Diabetes Endocrinol17 Feb 2025

   Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies

   Guideline or statementT2D & other

4. Lancet Diabetes Endocrinol14 Feb 2025

   Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

   Secondary analysisT2D & other

5. Lancet Diabetes Endocrinol7 Feb 2025

   Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy

   Cohort studyT1D

6. Lancet Diabetes Endocrinol5 Feb 2025

   Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects

   Cohort studyEndocrine cancer

7. Lancet Diabetes Endocrinol27 Jan 2025

   Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study

   Secondary analysisDiabetes in pregnancy

8. Lancet Diabetes Endocrinol24 Jan 2025

   Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

   Randomized controlled trialLipids & liver

9. Lancet Diabetes Endocrinol20 Jan 2025

   Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

   Secondary analysisT2D & other

10. Lancet Diabetes Endocrinol14 Jan 2025

    Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort

    Guideline or statementAdrenal

11. Lancet Diabetes Endocrinol14 Jan 2025

    Definition and diagnostic criteria of clinical obesity

    Guideline or statementObesity

12. Lancet Diabetes Endocrinol13 Jan 2025

    Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial

    Secondary analysisT2D & other

13. Lancet Diabetes Endocrinol16 Dec 2024

    Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study

    Cohort studyTechnology

14. Lancet Diabetes EndocrinolDecember 2024

    Time to reframe the disease staging system for type 1 diabetes

    Research articleT1D

15. Lancet Diabetes Endocrinol29 Nov 2024

    Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013–22): a longitudinal analysis of data from paediatric diabetes registries

    Cohort studyT1D

16. Lancet Diabetes Endocrinol25 Nov 2024

    Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

    Meta-analysisT2D & other

17. Lancet Diabetes Endocrinol22 Nov 2024

    Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial

    Randomized controlled trialEndocrine cancer

18. Lancet Diabetes Endocrinol15 Nov 2024

    Overweight and obesity among Israeli adolescents and the risk for serious morbidity in early young adulthood: a nationwide retrospective cohort study

    Cohort studyObesity

19. Lancet Diabetes Endocrinol13 Nov 2024

    Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial

    Research articleObesity

20. Lancet Diabetes Endocrinol11 Nov 2024

    Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium

    Cohort studyT2D & other

21. Lancet Diabetes Endocrinol24 Oct 2024

    Depression symptoms, wellbeing, health-related quality of life, and diabetes-related distress in novel subtypes of recent-onset diabetes in Germany: a 5-year observational follow-up study

    Cohort studyT2D & other

22. Lancet Diabetes Endocrinol23 Oct 2024

    Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)

    Secondary analysisT2D & other

23. Lancet Diabetes Endocrinol16 Oct 2024

    Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study

    Research articleLipids & liver

24. Lancet Diabetes Endocrinol7 Oct 2024

    Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013–17 in 63 countries worldwide: a population-based study

    Cohort studyEndocrine cancer

25. Lancet Diabetes Endocrinol4 Oct 2024

    Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study

    Cross-sectional studyT2D & other

26. Lancet Diabetes Endocrinol4 Oct 2024

    Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1

    Secondary analysisT2D & other

27. Lancet Diabetes Endocrinol23 Sep 2024

    Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies

    Cohort studyComplications

28. Lancet Diabetes Endocrinol6 Sep 2024

    Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

    Randomized controlled trialT2D & other

29. Lancet Diabetes Endocrinol6 Sep 2024

    Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France

    Cohort studyT1D

30. Lancet Diabetes Endocrinol6 Sep 2024

    Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

    Meta-analysisT2D & other

31. Lancet Diabetes EndocrinolSeptember 2024

    Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries

    Meta-analysisT2D & other

32. Lancet Diabetes Endocrinol29 Aug 2024

    Adiposity and metabolic health in Asian populations: an epidemiological study using dual-energy x-ray absorptiometry in Singapore

    Cross-sectional studyT2D & other

33. Lancet Diabetes Endocrinol5 Aug 2024

    Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation

    Cohort studyT2D & other

34. Lancet Diabetes Endocrinol1 Aug 2024

    Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    Cohort studyLipids & liver

35. Lancet Diabetes EndocrinolAugust 2024

    Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people

    Cohort studyT2D & other

36. Lancet Diabetes Endocrinol29 Jul 2024

    Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

    Randomized controlled trialObesity

37. Lancet Diabetes Endocrinol8 Jul 2024

    Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

    Meta-analysisT2D & other

38. Lancet Diabetes Endocrinol1 Jul 2024

    Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

    Randomized controlled trialLipids & liver

39. Lancet Diabetes Endocrinol24 Jun 2024

    Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts

    Cohort studyDiabetes in pregnancy

40. Lancet Diabetes Endocrinol3 Jun 2024

    Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study

    Cohort studyObesity

All 186 Briefs in ExploreShowing Briefs 81–120 of 186, newest first